Ultragenyx Pharmaceutical (RARE) Free Cash Flow (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Free Cash Flow data on file, last reported at -$198.0 million in Q1 2026.

• On a quarterly basis, Free Cash Flow fell 18.56% year-over-year to -$198.0 million in Q1 2026; TTM through Mar 2026 was -$503.0 million, a 24.51% decrease from a year earlier, with the FY2025 full-year figure at -$472.0 million, down 10.02% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$198.0 million, down from -$100.8 million in the prior quarter.
• Over the last five years, Free Cash Flow for RARE reached as high as -$51.4 million in Q4 2023 and fell as low as -$198.0 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$122.4 million across 5 years, with a median of -$111.5 million in 2025.
• Across the five-year window, Free Cash Flow sank 1041.85% in 2022 and soared 72.35% in 2023, its largest moves.
• Year by year, Free Cash Flow stood at -$186.0 million in 2022, then surged by 72.35% to -$51.4 million in 2023, then slumped by 70.09% to -$87.5 million in 2024, then decreased by 15.19% to -$100.8 million in 2025, then tumbled by 96.49% to -$198.0 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$198.0 million in Q1 2026, -$100.8 million in Q4 2025, and -$92.7 million in Q3 2025.